JP2013518086A5 - - Google Patents

Download PDF

Info

Publication number
JP2013518086A5
JP2013518086A5 JP2012550464A JP2012550464A JP2013518086A5 JP 2013518086 A5 JP2013518086 A5 JP 2013518086A5 JP 2012550464 A JP2012550464 A JP 2012550464A JP 2012550464 A JP2012550464 A JP 2012550464A JP 2013518086 A5 JP2013518086 A5 JP 2013518086A5
Authority
JP
Japan
Prior art keywords
radioimmunoconjugate
monoclonal antibody
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012550464A
Other languages
English (en)
Japanese (ja)
Other versions
JP5646652B2 (ja
JP2013518086A (ja
Filing date
Publication date
Priority claimed from NO20100143A external-priority patent/NO331080B1/no
Application filed filed Critical
Publication of JP2013518086A publication Critical patent/JP2013518086A/ja
Publication of JP2013518086A5 publication Critical patent/JP2013518086A5/ja
Application granted granted Critical
Publication of JP5646652B2 publication Critical patent/JP5646652B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012550464A 2010-01-29 2011-01-28 放射免疫コンジュゲートおよびその使用 Expired - Fee Related JP5646652B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29952410P 2010-01-29 2010-01-29
US61/299,524 2010-01-29
NO20100143A NO331080B1 (no) 2010-01-29 2010-01-29 Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
NO20100143 2010-01-29
PCT/EP2011/051231 WO2011092295A2 (en) 2010-01-29 2011-01-28 Novel radioimmunoconjugates and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014225005A Division JP5855209B2 (ja) 2010-01-29 2014-11-05 放射免疫コンジュゲートおよびその使用

Publications (3)

Publication Number Publication Date
JP2013518086A JP2013518086A (ja) 2013-05-20
JP2013518086A5 true JP2013518086A5 (https=) 2014-04-03
JP5646652B2 JP5646652B2 (ja) 2014-12-24

Family

ID=44319900

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012550464A Expired - Fee Related JP5646652B2 (ja) 2010-01-29 2011-01-28 放射免疫コンジュゲートおよびその使用
JP2014225005A Active JP5855209B2 (ja) 2010-01-29 2014-11-05 放射免疫コンジュゲートおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014225005A Active JP5855209B2 (ja) 2010-01-29 2014-11-05 放射免疫コンジュゲートおよびその使用

Country Status (25)

Country Link
US (2) US8628749B2 (https=)
EP (2) EP2528627B1 (https=)
JP (2) JP5646652B2 (https=)
KR (2) KR101893720B1 (https=)
CN (2) CN104338154B (https=)
AU (1) AU2011209441B2 (https=)
BR (1) BR112012018843B8 (https=)
CA (1) CA2786655C (https=)
DK (2) DK2705857T3 (https=)
ES (2) ES2469140T3 (https=)
HR (1) HRP20140538T1 (https=)
IL (2) IL221091A (https=)
MX (2) MX2012008695A (https=)
NO (1) NO331080B1 (https=)
NZ (1) NZ601055A (https=)
PH (2) PH12012501516A1 (https=)
PL (1) PL2528627T3 (https=)
PT (1) PT2528627E (https=)
RS (1) RS53346B (https=)
RU (2) RU2664475C1 (https=)
SG (1) SG182685A1 (https=)
SI (1) SI2528627T1 (https=)
UA (1) UA108631C2 (https=)
WO (1) WO2011092295A2 (https=)
ZA (1) ZA201205007B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2858964A1 (en) * 2011-12-13 2013-06-20 Nordic Nanovector As Chimeric therapeutic anti-cd37 antibodie hh1
RU2014140119A (ru) * 2012-03-30 2016-05-27 Иммьюноджен, Инк. Способы повышения эффективности терапии на основе cd37
CN103933575B (zh) * 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
CA2911962A1 (en) * 2013-06-07 2014-12-11 Roy H. Larsen Method for upregulating antigen expression
WO2015017552A1 (en) * 2013-08-01 2015-02-05 Agensys, Inc. Antibody drug conjugates (adc) that bind to cd37 proteins
JP6869187B2 (ja) * 2015-04-07 2021-05-12 メモリアル スローン ケタリング キャンサー センター ナノ粒子イムノコンジュゲート
GB201600328D0 (en) 2016-01-08 2016-02-24 Univ Oslo Hf Anti-CD37 chimeric antigen receptors and immune cells expressing them
US20190192703A1 (en) * 2016-09-16 2019-06-27 Nordic Nanovector Asa Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
KR102406510B1 (ko) 2017-07-03 2022-06-10 현대자동차주식회사 연료전지 시스템용 수소 공급 방법
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
EP3713607A1 (en) * 2017-11-22 2020-09-30 Nordic Nanovector ASA Radioimmunoconjugates in combination with other drugs as treatment against nhl
NZ781538A (en) 2019-04-24 2025-12-19 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
CA3137568A1 (en) * 2019-04-25 2020-10-29 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
CN117241832A (zh) * 2021-03-19 2023-12-15 海德堡医药研究有限责任公司 B淋巴细胞特异性的鹅膏毒素抗体缀合物
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
WO2023057583A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1
CN114081969A (zh) * 2021-11-23 2022-02-25 成都纽瑞特医疗科技股份有限公司 标记的小分子抗体、及其标记方法和应用
CN117285631A (zh) * 2023-11-24 2023-12-26 原子高科股份有限公司 用于放射性免疫治疗的Lu-177标记MUC1抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU2001259142C1 (en) * 2000-04-25 2006-11-23 Biogen Idec Inc. Intrathecal administration of rituximab for treatment of central nervous system lymphomas
RU2005122033A (ru) * 2002-12-13 2006-01-27 Митра Медикал Текнолоджи Аб (Se) Направленные противолимфомные средства с эффекторной и аффиновой функциями, связанные трехфункциональным реагентом
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
MXPA05008222A (es) * 2003-01-31 2005-10-05 Immunomedics Inc Metodos y composiciones para administrar agentes terapeuticos y de diagnostico.
WO2005084179A2 (en) * 2003-12-01 2005-09-15 Immunomedics, Inc. Improved method for preparing conjugates of proteins and chelating agents
RU2423381C2 (ru) 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
PE20140196A1 (es) * 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37

Similar Documents

Publication Publication Date Title
JP2013518086A5 (https=)
HRP20140538T1 (hr) Radioimunokonjugati i njihova primjena
Larson et al. Radioimmunotherapy of human tumours
JP2008530142A5 (https=)
JP2012034692A5 (https=)
JP2008540447A5 (https=)
JP2014533279A5 (https=)
JP2017501167A5 (https=)
RU2010145177A (ru) Лекарственное средство для лечения рака печени
JP2014502955A5 (https=)
JP2012046518A5 (https=)
JP2016502504A5 (https=)
JP2015534580A5 (https=)
JP2015534577A5 (https=)
JP2018522851A5 (https=)
JP2015534579A5 (https=)
JP2011046732A5 (https=)
JP2018513149A5 (https=)
JP2015532292A5 (https=)
RU2015154447A (ru) Способ повышения уровней экспрессии антигенов
NZ631405A (en) Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
JP2017510559A5 (https=)
JP2020527332A5 (https=)
JP2015527319A5 (https=)
JP2012509889A5 (https=)